



Distribution and Antibiotic Resistance Pattern of Bacteria Isolated from the Patients with Community-Acquired Urinary Tract Infections in Iran: A Cross-Sectional Study

Fatemeh Fallah¹, Soha Parhiz¹, Leila Azimi², Marjan Rashidan^{3*}

¹ Dept. of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

² Pediatric Infection Research Center, Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

³ School of medicine, Shahrood University of Medical Sciences, Shahrood, Iran.

Received: 10 July 2019

Accepted: 30 July 2019

Abstract

Background: Urinary Tract Infections (UTIs) remain the common infections diagnosed in outpatients as well as hospitalized patients. Multi-Drug Resistance (MDR) and Extensively-Drug Resistance (XDR) in the bacteria is an alarming problem in the world. Thus, the present study was conducted to detect the etiologic agents associated with Community-Acquired Urinary Tract Infections (CA-UTIs) and investigate the antibiotic susceptibility patterns.

Methods: This study was conducted on the outpatients referred to Labbafinejad Hospital Clinic, Tehran, Iran from September 2014 to March 2015. The bacterial pathogenic diversity was identified by standard laboratory methods. The antimicrobial resistance rates were determined by Kirby-Bauer disc diffusion method.

Results: A total of 303 patients were enrolled in this study, among which 204 (67.3%) of them were female and 99 (32.5%) of them were male. *Escherichia coli* was the dominant species (69%), followed by *Enterococcus faecalis* (12.8%), and *Klebsiella pneumoniae* (4.6%). High resistance rate was observed to nalidixic acid (73.8%), trimethoprim/Sulfamethoxazole (54.3%), ciprofloxacin (54.3%) in *E. coli*, and tetracycline (89.7%) in *E. faecalis* strains as well as high susceptibility rate to meropenem (96.6%), imipenem (95.2%), amikacin (90.4%), ceftoxitin (87.6%), and nitrofurantoin (82.8%) in *E. coli*, and nitrofurantoin (100%) in *E. faecalis* strains. In addition, 43.5% of the strains were found to be Multi-Drug-Resistant (MDR).

Conclusions: The results of this study showed that, *E. coli* was the predominant uropathogen of CA-UTIs in this geographical area. It was also found that, the empirical treatment of urinary tract infections may be difficult due to high resistance to commonly used antibiotics. Continuous monitoring of MDR organisms and drug resistance patterns is needed to prevent treatment failure and reduce selective pressure. These findings suggest the use of nitrofurantoin, ceftoxitin, and amikacin in this area of the country.

Keywords: Urinary tract infections, Bacteria, Antibiotic resistance.

*Corresponding to: M Rashidan, Email: marjan.rashidan@yahoo.com

Please cite this paper as: Fallah F, Parhiz S, Azimi L, rashidan M. Distribution and antibiotic resistance pattern of bacteria isolated from the patients with community-acquired urinary tract infections in iran: a cross-sectional study. Int J Health Stud 2018;4(2):14-19.

Introduction

Urinary tract infections (UTIs) remain the common infections diagnosed in outpatients as well as hospitalized patients and the second most common cause of bacterial infection after respiratory tract in both settings. It is also estimated that, on a global scale, about 150 million people each year suffer from UTI and cost at least 6 billion dollars worldwide.^{1,2} UTI is defined by the presence of 10⁵CFU/mL uropathogenic bacteria in urine and reported in both sexes and

in all age groups. The risk for UTIs in females is greater than males because of sexual activity, pregnancy and the short anatomy of the urethra.^{3,4} In addition, long-term antibiotic use can also be increased the risk of UTIs. This could damage the periurethral flora and cause the establishment and infection of uropathogenic bacteria in the urinary tract.^{5,6}

Most previously reported studies have shown that *Escherichia coli* is often a causative agent of UTI in both hospital and community-acquired infections. Additionally, *Enterococci*, *Klebsiella pneumoniae*, *Streptococcus agalactiae*, *Proteus mirabilis*, *Pseudomonas aeruginosa*, *Citrobacter freundii*, *Enterobacter cloacae* and *Acinetobacter* spp. are known as causative agents of UTI.⁷

Given the rapid evolutionary adaptation strategies of bacteria, the antibiotic resistance patterns of the uropathogens in the recent years have also significantly changed, both in the community and hospital infections.^{8,9}

On the other hand, treatment of UTI in the community is usually performed empirically before the result of the microbiological test; this can lead to the development of antibiotic resistance and treatment failure.¹⁰ Furthermore, improper use of broad spectrum antimicrobial agents and poor infection control strategies, also contributes to increasing antibiotic resistance and the development of multi-drug resistant bacteria (MDR) in these patients, which has become a serious public health concern.^{11,12} Recent studies have also shown an increase in antibiotic resistance in Iran, which there is no regular monitoring of the use of broad-spectrum antibiotics, so identification of local etiologic agents of UTIs and examination of antibiotic resistance patterns are essential to guide clinicians in empirical treatment in this geographical area. Therefore, the aim of this study was to detection of etiologic agents associated with community-acquired urinary tract infections (CA-UTIs) and investigation of antibiotic susceptibility patterns.

Materials and Methods

Isolate Collection and Identification

This cross-sectional descriptive study was conducted on the outpatients referred to Labbafinejad Hospital Clinic, Tehran, Iran from September 2014 to March 2015. Patients who treated with antibiotics or had a history of hospitalization were excluded from our study.

A midstream clean-catch urine specimen was collected from the outpatients and was inoculated on the Blood and

MacConkey (Merck, Germany) agar plates using calibrated loops. For colony count, the plates were incubated at 37°C for 24 hours. More than 10⁵ colony-forming unit per milliliter was considered as bacteriuria. Then, the plates were transferred to the Pediatric Infections Research Center of Shahid Beheshti University of Medical Science at Mofid children's Hospital for further investigations. Identification of bacterial agents was done by conventional biochemical procedures in the patients.¹³ All strains were stored at -70 °C in Trypticase Soy Broth (TSB) with 20% glycerol.

Antibiotic susceptibility of the studied strains was determined by the standard Kirby-Bauer disk diffusion method on Muller Hinton agar medium (MHA, Merck, Germany). The antibiotic discs of cefepime (CPM, 30µg), piperacillin (PRL, 100µg), ciprofloxacin (CIP, 5µg), amikacin (AK, 30µg), cefoxitin (FOX, 30µg), meropenem (MEM, 10µg), gentamicin (GEM, 10µg), ceftriaxone (CRO, 30µg), co-trimoxazole (SXT, 1.25/23.75µg), nitrofurantoin (NIT, 300µg), cefuroxime (CFM, 30µg), imipenem (IMI, 10µg), nalidixic acid (NA, 30µg), chloramphenicol (C, 30µg), ampicillin-sulbactam (SAM, 10µg), piperacillin-tazobactam (PTZ, 100µg), cefotaxime (CTX, 30µg), ceftazidime (CAZ, 30µg), ofloxacin (OFX, 5 µg), tigecycline (TGC, 15µg), ticarcillin (TIC, 75µg), aztreonam (ATM, 30µg), tobramycin (TOB, 10µg), clindamycin (CD, 2µg), erythromycin (ERY, 15µg), synergid (SYN, 15µg), linezolid (LZD, 30µg), ampicillin (AP, 10µg), tetracycline (TET, 30µg), minocycline (MN, 30µg), levofloxacin (LEV, 5µg), gatifloxacin (GAT, 5µg), vancomycin (VAN, 30µg), high-level gentamicin (GEM, 120µg) and penicillin G (PEN, 10unit) were used (MAST group Ltd., United Kingdom) in this study. The results were interpreted according to the standard recommendation of the Clinical and Laboratory Standard Institute guidelines (CLSI 2014).¹⁴ Control tests were conducted using reference strains of *E. coli* ATCC 25922, *Staphylococcus aureus* ATCC 25923, *Streptococcus pneumoniae* ATCC 49619 and *P. aeruginosa* ATCC 27853.

Statistical Analysis

The data were analyzed using WHONET software 5.6 provided by the World Health Organization for antimicrobial resistance surveillance of uropathogenic bacteria.^{15,16} Antibiotic resistance percentage and the rate of multi-drug resistance strains were also evaluated. According to the European Center for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC), multi-drug resistance strains are divided into MDR (Multiple Drug-Resistant), XDR (Extensively Drug-Resistant) and PDR (Pan Drug-Resistant).¹⁷ MDR bacteria are defined as non-susceptibility to at least one agent in 3 or more antimicrobial categories, XDR bacteria are defined as non-susceptibility to at least 1 agent in all but 2 or fewer antimicrobial categories and the PDR bacteria are defined as non-susceptibility to all agents in all antimicrobial categories.

Results

A total of 303 patients were enrolled in this study, including 204 (67.3%) females and 99 (32.5%) males with an

age range from 4 to 90 years old. Hence, with respect to gender, females had a higher prevalence of infection than males. The prevalence of UTI was significantly associated with the gender ($P.V=0.0001$).

Distribution of Uropathogenic Bacteria

9 different species of bacteria were isolated from the urine samples with significant bacterial growth. 82.1 % of the isolates had Gram-negative bacteria while, only 17.7% of them had Gram-positive bacteria (table 1). *E. coli* was the most common bacteria isolated (N=210, 69%), followed by *Enterococcus faecalis* (N=39, 12.8%), and *Klebsiella pneumoniae* (N=14, 4.6%).

Table 1. Frequency of the isolated uropathogenic bacteria

Table 1. Frequency of uropathogenic bacteria isolated			
Bacteria	Frequency (%)	Gram reaction (%)	Total
<i>Escherichia coli</i>	210 (69%)		303
<i>Klebsiella pneumoniae</i>	14 (4.6%)		
<i>Acinetobacter</i> spp.	8 (2.6%)		
<i>Pseudomonas aeruginosa</i>	8 (2.6%)	Gram-negative N= 249 (82.1%)	
<i>Citrobacter</i> spp.	4 (1.3%)		
<i>Proteus</i> spp.	3 (0.9%)		
<i>Enterobacter</i> sp.	1 (0.3%)		
<i>Edwardsiella</i> sp.	1 (0.3%)		
<i>Streptococcus agalactiae</i>	11 (3.6%)		
<i>Enterococcus</i> spp.		Gram-positive N= 54 (17.8%)	
– <i>E. faecalis</i>	39 (12.8%)		
– <i>E. faecium</i>	4 (1.3%)		

Antibiotic Resistance of Uropathogenic Bacteria

Table 2 shows the prevalence of resistance among uropathogenic Gram-negative bacteria. *E. coli* showed the lowest resistance to meropenem (3.3%) and highest against nalidixic acid (73.8%). More than half of *K. pneumoniae* were resistant to nitrofurantoin and piperacillin (57.1%) and 92.8% of them were sensitive to piperacillin/tazobactam. *Proteus* spp. was mostly resistant to trimethoprim/sulfamethoxazole, nitrofurantoin, nalidixic acid, and chloramphenicol (100%) and was also sensitive to piperacillin, amikacin, cefoxitin, meropenem, and cefuroxime (100%). *Citrobacter* spp. had 100% susceptibility to cefepime, amikacin, gentamicin, trimethoprim/sulfamethoxazole, imipenem, nalidixic acid and piperacillin/tazobactam. The least effective antibiotic in this isolate was nitrofurantoin. *Enterobacter* spp. was generally resistant to most of our tested antibiotics. This isolate did not show resistance to antibiotics such as amikacin, cefoxitin, meropenem, nitrofurantoin, imipenem, and chloramphenicol. *Edwardsiella* spp. was generally susceptible to our tested antibiotics. The least effective antibiotics in this isolate were piperacillin, gentamicin, trimethoprim/sulfamethoxazole, and ampicillin/sulbactam. *Acinetobacter* spp. showed the highest resistance to ceftriaxone and cefotaxime (87.5%) and lowest against meropenem and imipenem (37.5%). *P. aeruginosa* exhibited the highest resistance to gentamicin (75%) and lowest against piperacillin, ciprofloxacin, and imipenem (12.5%).

Table 2. Antibiotic resistance of uropathogenic Gram-negative bacteria against tested antibiotics

Table 2. Antibiotic resistance of uropathogenic Gram-negative bacteria against tested antibiotics

Antibiotic disks	Resistance rate, %							
	E.coli N=210	K. pneumonia N=14	Proteus spp N=3	Citrobacter spp N=4	Enterobacter spp N=1	Edwardsiella Spp N=1	Acinetobacter spp N=8	P. aeruginosa N=8
Piperacillin	147(70%)	8(57.1%)	0(0%)	2(50%)	1(100%)	1(100%)	5(62.5%)	1(12.5%)
Ciprofloxacin	114(54.3%)	4(28.5%)	1(33.3%)	1(25%)	1(100%)	0(0%)	6(75%)	1(12.5%)
Cefepime	50(23.8%)	3(21.4%)	1(33.3%)	0(0%)	1(100%)	0(0%)	8(100%)	3(37.5%)
Amikacin	20(9.5%)	2(14.3%)	0(0%)	0(0%)	0(0%)	0(0%)	6(75%)	4(50%)
Cefoxitin	26(12.4%)	3(21.4%)	0(0%)	1(25%)	0(0%)	0(0%)	-	-
Meropenem	7(3.3%)	1(7.1%)	0(0%)	1(25%)	0(0%)	0(0%)	3(37.5%)	0(0%)
Gentamicin	50(23.8%)	2(14.2%)	1(33.3%)	0(0%)	1(100%)	1(100%)	5(62.5%)	6(75%)
Ceftriaxone	95(45.2%)	5(35.7%)	1(33.3%)	1(25%)	1(100%)	0(0%)	7(87.5%)	-
Trimethoprim/Sulfamethoxazole	114(54.3%)	6(42.8%)	3(100%)	0(0%)	1(100%)	1(100%)	5(62.5%)	-
Nitrofurantoin	36(17.1%)	8(57.1%)	3(100%)	4(100%)	0(0%)	0(0%)	6(75%)	-
Cefuroxime	101(48.1%)	5(35.7%)	0(0%)	1(25%)	1(100%)	0(0%)	6(75%)	-
Imipenem	10(4.8%)	3(21.4%)	1(33.3%)	0(0%)	0(0%)	0(0%)	3(37.5%)	1(12.5%)
Nalidixic Acid	155(73.8%)	5(35.7%)	3(100%)	0(0%)	1(100%)	0(0%)	-	-
Chloramphenicol	20(9.5%)	3(21.4%)	3(100%)	1(25%)	0(0%)	0(0%)	-	-
Ampicillin-sulbactam	90(42.9%)	5(35.7%)	2(66.7%)	1(25%)	1(100%)	1(100%)	5(62.5%)	-
Piperacillin/Tazobactam	16(7.6%)	1(7.1%)	1(33.3%)	0(0%)	1(100%)	0(0%)	0(0%)	0(0%)
Cefotaxime	-	-	-	-	-	-	7(87.5%)	5(62.5%)
Ofloxacin	-	-	-	-	-	-	-	2(25%)
Ceftazidim	-	-	-	-	-	-	5(62.5%)	5(62.5%)
Tetracycline	-	-	-	-	-	-	6(75%)	-
Tigecycline	-	-	-	-	-	-	6(75%)	-
Ticarcillin	-	-	-	-	-	-	-	3(37.5%)
Aztreonam	-	-	-	-	-	-	-	3(37.5%)
Tobramycin	-	-	-	-	-	-	-	5(62.5%)

Table 3 shows the prevalence of resistance among uropathogenic Gram-positive bacteria. High levels of tetracycline and minocycline resistance were observed in *E. faecalis* strains (89.7 and 87%). These strains did not show resistance to antibiotics such as vancomycin, nitrofurantoin, and linezolid. All 11 isolates of *S. agalactiae* were susceptible to erythromycin, ofloxacin, cefotaxime, ampicillin and linezolid and resistant to vancomycin.

Table 3. Antibiotic resistance of uropathogenic Gram-positive bacteria against tested antibiotics

Multi-Resistant Uropathogenic Bacteria

Table 3. Antibiotic resistance of uropathogenic Gram-positive bacteria against tested antibiotics

Antibiotic disks	Resistance rate, %		
	<i>E. faecalis</i> N=39	<i>E. faecium</i> N=4	<i>S. agalactiae</i> N=11
Penicillin G	3(7.6%)	2(50%)	-
Vancomycin	0(0%)	1(25%)	11(100%)
Tetracycline	35(89.7%)	2(50%)	-
Minocycline	34(87%)	2(50%)	-
Ciprofloxacin	10(25.6%)	2(50%)	-
Levofloxacin	9(23%)	2(50%)	0(0%)
Gatifloxacin	9(23%)	2(50%)	-
Nitrofurantoin	0(0%)	1(25%)	-
Gentamicin (120 µg)	14(35.8%)	1(25%)	-
Erythromycin	-	-	0(0%)
Ofloxacin	-	-	0(0%)
Cefotaxime	-	-	0(0%)
Ampicillin	2 (5.1%)	2(50%)	0(0%)
Linezolid	0(0%)	1(25%)	0(0%)
Synercid	-	-	1(9.09%)
Clindamycin	-	-	0(0%)

Phenotypic detection of multi-resistant strains was carried out by WHONET software 5.6 as MDR, possible XDR or possible PDR (Figure 1). Among bacterial species presented, *Acinetobacter* spp. showed the highest percentage of MDR and XDR, 6(75%) and 5(62.5%) isolates, respectively. Among a total of 233 isolates of Enterobacteriaceae tested, 113 (48.4%) isolates were found to be MDR, 9 (3.8%) isolates were possible XDR and 1(0.4%) isolate was found to be PDR. In the Gram-positive bacteria, *Enterococcus* spp. showed 10(23.2%) isolates of MDR and 1 (2.3%) isolate of XDR.

MDR: Multi-Drug Resistant, Possible XDR; Extensively drug-resistant, Possible PDR; Pan drug-resistant

Discussion

Today, the increased antimicrobial resistance and the emergence of MDR bacteria causing CA-UTIs has become a serious public health concern resulting from the irrational and improper use of antimicrobials and the presence of antibiotics in the food chain.¹⁸ Thus, an amendment to the current antimicrobial stewardship program is needed in this geographical area to improve the efficacy of CA-UTIs treatment.

In our study, the prevalence of UTI was significantly higher in females than males attributing to the physical and anatomical factors in females.^{3,4} These findings were in accordance with the findings of similar studies in CA-UTIs.^{19,20}




Figure 1. Percentage of multi-drug resistance of uropathogenic bacteria. MDR; Multi-drug resistant, Possible XDR; Extensively drug-resistant, Possible PDR; Pan drug-resistant

Enterobacteriaceae are the most common cause of UTI in hospitals and the community, and are responsible for many current problems caused by transferable multi-antibiotic resistance.²¹ Therefore, the ability to monitor the antimicrobial resistance trends in infections most commonly caused by these organisms, across all patient groups will provide valuable additional insight needed to inform public health action. In this study, the Gram-negative bacilli accounted for 84.43% of the total bacterial isolates, while Gram-positive cocci accounted for 15.57% of the total bacterial isolates. As expected, *E. coli* was the most prevalent uropathogen (69%) in CA-UTIs. This finding is in agreement with the previous studies conducted in Iran (51.5%),²² as well as European studies (76%)²³ and studies carried out in Germany (74.5%)²⁴ and Denmark²⁵ but is higher than the reports from Ethiopia (39.4%)²⁶ and Nigeria (40.7%).²⁷ In this study, *E. faecalis* was the second predominate isolate accounting for 12.8% of the total bacterial isolates. This result was consistent with a similar study conducted in India²⁰ and Korea²⁸ and was contrary to other studies.^{11,29,30} The similarities and differences in the type and distribution of uropathogens may be related to various environmental conditions and host factors and practices, such as health and educational programs and social and economic hygiene standards in each country.

Understanding the antibiotic resistance patterns in *E. coli*, as the most frequent uropathogen is important to choose an empirical antimicrobial therapy. As shown in table 2, *E. coli* showed high level of resistance to nalidixic acid (73.8%) and piperacillin (70%) followed by ciprofloxacin and trimethoprim/sulfamethoxazole (54.3%). The current results are similar to the previous studies conducted on CA-UTIs in Iran^{31,32} and are less than that reported in other surveys performed in other parts of the world.³³⁻³⁶

On the other hand, ciprofloxacin and trimethoprim/sulfamethoxazole are used as a first -choice treatment for CA-UTIs in our region. The widespread use of these antimicrobials in the treatment of community-acquired infections may have contributed to the high levels of observed resistance. Therefore, these antibiotics should be carefully considered for empirical treatment. Maximum sensitivity was reported towards meropenem (96.6%), imipenem (95.2%), piperacillin/tazobactam (92.3%), chloramphenicol (90%) and amikacin (90.4%) followed by ceftazidime (87.6%), nitrofurantoin (82.8%), gentamicin and cefepime (76%). Similar results were reported in the studies conducted in other countries.^{34,37,38} In another study, *E. coli* strains were highly resistant against ceftazidime (85%) and nitrofurantoin (80%) followed by ceftazidime (69%), gentamicin (64%) and amikacin (51%).³⁹ Therefore, our findings suggest that, nitrofurantoin is an appropriate empirical choice for treatment of CA-UTIs in this region. In this regards, different patterns of antimicrobial resistance in different regions may be due to the regional variation in antibiotic practice patterns.

In this study, the highest percentage of *E. faecalis* isolates was resistant to Tetracyclines (tetracycline, 89.7 and minocycline, 87%). This frequency was similar to the resistance rates reported in Taiwan (91.8%),⁴⁰ Iran (90.3%)⁴¹ and Iraq (100%),⁴² but higher than those reported in India (50%) and Brazil (59.2%).^{40,43} The high-level resistance to Tetracyclines in these strains may be attributed to the overuse of antibiotics to treat human diseases and livestock in Iran.⁴⁴ Therefore, it is necessary to monitor the use of the antimicrobial in the community and to evaluate animal reservoirs of tetracycline-resistant *E. faecalis* strains. The most susceptibility was observed to vancomycin, nitrofurantoin, linezolid, ampicillin, and penicillin. The high susceptibility to these antibiotics, making them the first line of treatment for

CA-UTIs, as long as, the microbiological information is known.

Among 302 isolates, 43.5% of them were found to be multi-drug resistant. In this survey, a significant higher percentage of MDR and the possible XDR strains from CA-UTIs was observed. Among the tested uropathogens, *Acinetobacter* spp. exhibited the highest rates of MDR and the possible XDR followed by *E. coli* and *P. aeruginosa*. In our report, only *K. pneumonia* isolates were found to be the possible PDR phenotype. The contributing factors for the emergence of such a high bacterial antibiotic resistance in CA-UTIs may be the use of antibiotics in livestock, self-medication, excessive availability of antibiotics, dispensing them without proper prescriptions, non-compliance with an antibiotic regimen by patients, and indiscriminate use of antibiotics. The involvement of such drug-resistant bacteria in the development of community-acquired infections is a very serious concern in terms of public health. Therefore, some necessary steps should be taken immediately to control the situation.

The results of the current study showed an overview of the species diversity of the uropathogenic bacteria and antibiotic resistance patterns in Iran's community. A high prevalence of multi-drug resistance and the possible XDR strains were observed among uropathogenic bacteria. In particular, resistance to nalidixic acid, cotrimoxazole and ciprofloxacin was higher, thus the use of these drugs should be avoided for empirical UTI-based treatment. In such cases, empirical treatment with nitrofurantoin, cefoxitin and amikacin may provide better antibiotic coverage. These findings suggest the need for continuous antimicrobial surveillance of multi-drug resistance uropathogenic bacteria to fight the UTI caused by these bacterial pathogens.

Acknowledgement

The authors would like to thank the Pediatric Infectious Disease Research Center of Shahid Beheshti University of Medical Sciences for their support. The authors would also like to thank the members of the vice-chancellery in research affairs and those who assisted in the study.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

- Gonzalez CM, Schaeffer AJ. Treatment of urinary tract infection: what's old, what's new, and what works. *World J Urol* 1999;17:372-82.
- Najar MS, Saldanha CL, Bandy KA. Approach to urinary tract infections. *Indian J Nephrol* 2009;19:129-39. doi:10.4103/0971-4065.59333
- Mishra MP, Sarangi R, Padhy RN. Prevalence of multidrug resistant uropathogenic bacteria in pediatric patients of a tertiary care hospital in eastern India. *J Infect Public Health* 2016;9:308-14. doi:10.1016/j.jiph.2015.10.002
- Haque R, Akter ML, Salam MA. Prevalence and susceptibility of uropathogens: a recent report from a teaching hospital in Bangladesh. *BMC Res Notes* 2015;8:416. doi:10.1186/s13104-015-1408-1
- Abejew AA, Denboba AA, Mekonnen AG. Prevalence and antibiotic resistance pattern of urinary tract bacterial infections in Dessie area, North-East Ethiopia. *BMC Res Notes* 2014;7:687. doi:10.1186/1756-0500-7-687
- Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol* 2015;13:269-84. doi:10.1038/nrmicro3432
- Farajnia S, Alikhani MY, Ghotaslou R, Naghili B, Nakhband A. Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran. *Int J Infect Dis* 2009;13:140-4. doi:10.1016/j.ijid.2008.04.014
- Komolafe OO. Antibiotic resistance in bacteria - an emerging public health problem. *Malawi Med J* 2003;15:63-7.
- Jahn LJ, Munck C, Ellabaan MMH, Sommer MOA. Adaptive laboratory evolution of antibiotic resistance using different selection regimes lead to similar phenotypes and genotypes. *Front Microbiol* 2017;8:816. doi:10.3389/fmicb.2017.00816
- Akoachere JF, Yvonne S, Akum NH, Seraphine EN. Etiologic profile and antimicrobial susceptibility of community-acquired urinary tract infection in two Cameroonian towns. *BMC Res Notes* 2012;5:219. doi:10.1186/1756-0500-5-219
- Mihankhah A, Khoshbakht R, Raeisi M, Raeisi V. Prevalence and antibiotic resistance pattern of bacteria isolated from urinary tract infections in Northern Iran. *J Res Med Sci* 2017;22:108. doi:10.4103/jrms.JRMS_889_16
- Frieri M, Kumar K, Boutin A. Antibiotic resistance. *Journal of infection and public health* 2017;10:369-78.
- Bergey DH, Holt JG. *Bergey's manual of determinative bacteriology*. 9th ed. USA: Baltimore : Williams & Wilkins; 1994.
- Clinical and Laboratory Standards Institute, Performances Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI Document M100-S24, Wyne2014.
- Cullen IM, Manecksha RP, McCullagh E, Ahmad S, O'Kelly F, Flynn RJ, et al. The changing pattern of antimicrobial resistance within 42,033 *Escherichia coli* isolates from nosocomial, community and urology patient-specific urinary tract infections, Dublin, 1999-2009. *BJU Int* 2012;109:1198-206. doi:10.1111/j.1464-410X.2011.10528.x
- O'Brien TF, Stelling J. Integrated multilevel surveillance of the world's infecting microbes and their resistance to antimicrobial agents. *Clin Microbiol Rev* 2011;24:281-95. doi:10.1128/CMR.00021-10
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18:268-81. doi:10.1111/j.1469-0691.2011.03570.x
- van Duin D, Paterson DL. Multidrug resistant bacteria in the community: trends and lessons learned. *Infect Dis Clin North Am* 2016;30:377-90. doi:10.1016/j.idc.2016.02.004
- Orrett FA. Urinary tract infections in general practice in a rural community in South Trinidad. *Saudi Med J* 2001;22:537-40.
- Gupta S, Kapur S, Padmavathi D. Comparative prevalence of antimicrobial resistance in community-acquired urinary tract infection cases from representative States of northern and southern India. *J Clin Diagn Res* 2014;8:De09-12. doi:10.7860/JCDR/2014/9349.4889
- Baral P, Neupane S, Marasini BP, Ghimire KR, Lekhak B, Shrestha B. High prevalence of multidrug resistance in bacterial uropathogens from Kathmandu, Nepal. *BMC Res Notes* 2012;5:38. doi:10.1186/1756-0500-5-38
- Nozarian Z, Abdollahi A. Microbial etiology and antimicrobial susceptibility of bacteria implicated in urinary tract infection in Tehran, Iran. *Iran J Pathol* 2015;10:54-60.
- Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. *Int J Antimicrob Agents* 2009;34:407-13. doi:10.1016/j.ijantimicag.2009.04.012
- Klingeberg A, Noll I, Willrich N, Feig M, Emrich D, Zill E, et al. Antibiotic-resistant *E. coli* in uncomplicated community-acquired urinary tract infection. *Dtsch Arztebl Int* 2018;115:494-500. doi:10.3238/arztebl.2018.0494
- Cordoba G, Holm A, Hansen F, Hammerum AM, Bjerrum L. Prevalence of antimicrobial resistant *Escherichia coli* from patients with suspected urinary tract infection in primary care, Denmark. *BMC Infect Dis* 2017;17:670. doi:10.1186/s12879-017-2785-y

26. Seifu WD, Gebissa AD. Prevalence and antibiotic susceptibility of Uropathogens from cases of urinary tract infections (UTI) in Shashemene referral hospital, Ethiopia. *BMC Infect Dis* 2018;18:30. doi:10.1186/s12879-017-2911-x
27. Ehinmidu JO. Antibiotics susceptibility patterns of urine bacterial isolates in Zaria, Nigeria. *Trop J Pharm Res* 2003;2:223-8. doi:10.4314/tjpr.v2i2.14603
28. Lee SJ, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, et al. Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System. *J Infect Chemother* 2011;17:440-6. doi:10.1007/s10156-010-0178-x
29. Nzalie RN, Gonsu HK, Koulla-Shiro S. Bacterial etiology and antibiotic resistance profile of community-acquired urinary tract infections in a Cameroonian city. *International journal of microbiology* 2016;2016:1-7. doi:10.1155/2016/3240268
30. Sharma I, Paul D. Prevalence of community acquired urinary tract infections in Silchar Medical College, Assam, India and its antimicrobial susceptibility profile. *Indian J Med Sci* 2012;66:273-9. doi:10.4103/0019-5359.115749
33. Ramirez-Castillo FY, Moreno-Flores AC, Avelar-Gonzalez FJ, Marquez-Diaz F, Harel J, Guerrero-Barrera AL. An evaluation of multidrug-resistant *Escherichia coli* isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. *Ann Clin Microbiol Antimicrob* 2018;17:34. doi:10.1186/s12941-018-0286-5
34. Thapa P, Parajuli K, Poudel A, Thapa A, Manandhar B, Laudari D, et al. Causative agents and susceptibility of antimicrobials among suspected females with urinary tract infection in tertiary care hospitals of western nepal. *Journal of Chitwan Medical College* 2013;3:16-9.
35. Moroh J-LA, Fleury Y, Tia H, Bahi C, Lietard C, Coroller L, et al. Diversity and antibiotic resistance of uropathogenic bacteria from Abidjan. *African Journal of Urology* 2014;20:18-24. doi:10.1016/j.afju.2013.11.005
36. Ali I, Kumar N, Ahmed S, Dasti JI. Antibiotic resistance in uropathogenic *e. coli* strains isolated from non-hospitalized patients in Pakistan. *J Clin Diagn Res* 2014;8:De01-4. doi:10.7860/JCDR/2014/7881.4813
37. Shilpi T, Ahmed MN, Ariful Huq SM, Baul SK, Khatun M. Isolation of bacteria causing urinary tract infections and their antibiotic susceptibility profile at Anwer Khan Modern Medical College Hospital. *Anwer Khan Modern Medical College Journal* 2013;4:23-7.
38. Kidwai SS, Nageen A, Ghaznavi S, Bashir F, Ara J. Antibiotic susceptibility in commonly isolated pathogens from urinary tract infection in a cohort of subjects from low socioeconomic strata. *Pak J Med Sci* 2017;33:254-9. doi:10.12669/pjms.332.11569
39. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. *Ann Clin Microbiol Antimicrob* 2007;6:4. doi:10.1186/1476-0711-6-4
40. Kiffer CR, Mendes C, Oplustil CP, Sampaio JL. Antibiotic resistance and trend of urinary pathogens in general outpatients from a major urban city. *Int Braz J Urol* 2007;33:42-8. doi:10.1590/s1677-55382007000100007
41. Rashidan M, Ghalavand Z, Eslami G, Gachkar L, Rahbar M, Khosravi R, et al. Molecular detection of antibiotic resistance genes among *Enterococcus faecalis* isolated from fecal and urine samples of patients with community-acquired urinary tract infections. *Arch Pediatr Infect Dis* 2016;4:1-8. doi:10.5812/pedinfect.36262
42. Khalid HM. Molecular detection of virulence factors of *enterococcus faecalis* isolated from urine samples in Duhok City, Kurdistan Region/Iraq. *Sci J Univ Zakho* 2016;4:63-72. doi:10.25271/2016.4.1.24
43. Singhal A, Sharma R, Jain M, Vyas L. Hospital and community isolates of uropathogens and their antibiotic sensitivity pattern from a tertiary care hospital in North West India. *Ann Med Health Sci Res* 2014;4:51-6. doi:10.4103/2141-9248.126611
44. Asadpour L. Antibacterial drug resistance patterns in poultry isolated *enterococci*. *Afr J Microbiol Res* 2012;6:5857-61. doi:10.5897/AJMR12.187